Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus

Circulation

Volumn 135, Issue 16, 2017, Pages 1522-1531

  Rawshani, Aidin ^a,b   Rawshani, Araz ^a,b   Franzén, Stefan ^b   Eliasson, Björn ^a,b   Svensson, Ann Marie ^b   Miftaraj, Mervete ^b   McGuire, Darren K ^c   Sattar, Naveed ^d   Rosengren, Annika ^a   Gudbjörnsdottir, Soffia ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Centre of Registers   (Sweden)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cardiology; cardiovascular diseases; diabetes mellitus; heart failure; mortality survival; risk factors

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE CONTROL; FEMALE; FOLLOW UP; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; COMPLICATION; MORTALITY; RISK FACTOR;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85014001844     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025961     Document Type: Article

References (19)

1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653. doi: 10.1056/NEJMoa052187.
2. Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972-1982. doi: 10.1056/NEJMoa1408214.
3. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313:37-44. doi: 10.1001/jama.2014.16425.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393. doi: 10.1056/NEJMoa021778.
5. Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB, Sperling L, Rutter MK; BARI 2D Study Group. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D Trial. J Am Coll Cardiol. 2015;66:765-773. doi: 10.1016/j.jacc.2015.06.019.
6. Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA, Segal J, Butler MG, Karter AJ, Steiner JF, Newton KM, Morales LS, Pathak RD, Thomas A, Reynolds K, Kirchner HL, Waitzfelder B, Elston Lafata J, Adibhatla R, Xu Z, O'Connor PJ. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care. 2015;38:905-912. doi: 10.2337/dc14-1877.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
8. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
9. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, Zinman B, Eckel RH. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130:1110-1130. doi: 10.1161/CIR.0000000000000034.
10. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378:140-146. doi: 10.1016/S0140-6736(11)60471-6.
11. Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A, Pivodic A, Gudbjörnsdottir S, Lind M. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:876-885. doi: 10.1016/S2213-8587(15)00292-2.
12. Eliasson B, Gudbjörnsdottir S. Diabetes care: improvement through measurement. Diabetes Res Clin Pract. 2014;106(suppl 2):S291-S294. doi: 10.1016/S0168-8227(14)70732-6.
13. Rawshani A, Landin-Olsson M, Svensson AM, Nyström L, Arn-qvist HJ, Bolinder J, Gudbjörnsdottir S. The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods. Diabetologia. 2014;57:1375-1381. doi: 10.1007/s00125-014-3225-9.
14. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdóttir S, Eli-asson B; Steering Committee of the Swedish National Diabetes Register. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care. 2007;30:496-502. doi: 10.2337/dc06-1406.
15. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Re-uterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186/1471-2458-11-450.
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591. doi: 10.1056/NEJMoa0706245.
17. Nyström T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Gly-cemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015;66:535-543. doi: 10.1016/j. jacc.2015.05.054.
18. Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes Endocrinol. 2013;1:71-78. doi: 10.1016/S2213-8587(13)70025-1.
19. Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, Zethelius B, Avdic T, Landin-Olsson M, Jendle J, Gudbjörnsdóttir S; Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234.